CRISPR Gene Therapy Cures Sickle Cell Disease

CRISPR gene therapy achieved a pivotal breakthrough in 2025, curing sickle cell disease in over 90% of treated patients with two-year symptom-free status. Expanded clinical results from Vertex Pharmaceuticals and CRISPR Therapeutics demonstrated the therapy as curative in 29 of 31 patients in one study, outperforming #5 in its clear demonstration of transformative genetic medicine. This success follows FDA approval in December 2023 and marks the strongest evidence yet of CRISPR's potential. With 95% of treated individuals showing sustained remission, the therapy represents a data-driven milestone, faster than the average cure rate for previous genetic interventions.